Literature DB >> 8391917

The value of reoperation for recurrent glioblastoma.

P Dirks1, M Bernstein, P J Muller, W S Tucker.   

Abstract

To determine the value of reoperation alone (no further surgical procedures or radiotherapy), 43 patients (27 men, 16 women) with recurrent supratentorial glioblastomas who underwent a second craniotomy for recurrent tumour were reviewed retrospectively. The patients ranged in age from 27 to 66 years (median 53 years). All patients were treated initially by surgical resection and external radiation (50 Gy in 25 fractions through parallel opposed regional fields). In addition, 10 patients (23%) received chemotherapy, 3 patients (7%) received photodynamic therapy and 9 patients (21%) received interstitial brachytherapy postoperatively. Although none of the patients had further surgical procedures or radiotherapy after reoperation for tumour recurrence, 5 of the 43 did receive single-agent chemotherapy. The median survival after the first operation was 57 weeks. The median interval between first and second operations was 32 weeks. Median survival after reoperation was 19 weeks. An interval of more than 50 weeks between the two operations correlated with a significant (p < 0.05) increase in survival. The death rate for reoperation was 4.6%. The infection rate was 9.3%. The authors conclude that reoperation alone confers a modest but valuable increase in survival, especially if the interval between operations is greater than 50 weeks.

Entities:  

Mesh:

Year:  1993        PMID: 8391917

Source DB:  PubMed          Journal:  Can J Surg        ISSN: 0008-428X            Impact factor:   2.089


  47 in total

1.  Scale to predict survival after surgery for recurrent glioblastoma multiforme.

Authors:  John K Park; Tiffany Hodges; Leopold Arko; Michael Shen; Donna Dello Iacono; Adrian McNabb; Nancy Olsen Bailey; Teri Nguyen Kreisl; Fabio M Iwamoto; Joohee Sul; Sungyoung Auh; Grace E Park; Howard A Fine; Peter McL Black
Journal:  J Clin Oncol       Date:  2010-07-19       Impact factor: 44.544

2.  Thymidine kinase gene delivery using curcumin loaded peptide micelles as a combination therapy for glioblastoma.

Authors:  Jin Hyeong Park; Jaesik Han; Minhyung Lee
Journal:  Pharm Res       Date:  2014-08-27       Impact factor: 4.200

3.  Patterns of failure after radiosurgery to two different target volumes of enhancing lesions with and without FLAIR abnormalities in recurrent glioblastoma multiforme.

Authors:  Eun Young Kim; Raphael Yechieli; Jin Koo Kim; Tom Mikkelsen; Steven N Kalkanis; Jack Rock; Mark Rosenblum; Samuel Ryu
Journal:  J Neurooncol       Date:  2013-10-31       Impact factor: 4.130

4.  Large volume re-irradiation with bevacizumab is a feasible salvage option for patients with refractory high-grade glioma.

Authors:  Michael Back; Cecelia E Gzell; Marina Kastelan; Linxin Guo; Helen R Wheeler
Journal:  Neurooncol Pract       Date:  2014-12-15

5.  A practical scoring system to determine whether to proceed with surgical resection in recurrent glioblastoma.

Authors:  Chul-Kee Park; Jeong Hoon Kim; Do-Hyun Nam; Chae-Yong Kim; Sang-Bong Chung; Young-Hoon Kim; Ho Jun Seol; Tae Min Kim; Seung Hong Choi; Se-Hoon Lee; Dae Seog Heo; Il Han Kim; Dong Gyu Kim; Hee-Won Jung
Journal:  Neuro Oncol       Date:  2013-06-25       Impact factor: 12.300

6.  Fractionated stereotactic reirradiation and concurrent temozolomide in patients with recurrent glioblastoma.

Authors:  G Minniti; V Armosini; M Salvati; G Lanzetta; P Caporello; M Mei; M F Osti; R Enrici Maurizi
Journal:  J Neurooncol       Date:  2010-11-05       Impact factor: 4.130

7.  Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas.

Authors:  Kyle C Cuneo; James J Vredenburgh; John H Sampson; David A Reardon; Annick Desjardins; Katherine B Peters; Henry S Friedman; Christopher G Willett; John P Kirkpatrick
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-04-12       Impact factor: 7.038

8.  Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastoma.

Authors:  Graziella Filippini; Chiara Falcone; Amerigo Boiardi; Giovanni Broggi; Maria G Bruzzone; Dario Caldiroli; Rita Farina; Mariangela Farinotti; Laura Fariselli; Gaetano Finocchiaro; Sergio Giombini; Bianca Pollo; Mario Savoiardo; Carlo L Solero; Maria G Valsecchi
Journal:  Neuro Oncol       Date:  2007-11-09       Impact factor: 12.300

9.  Factors impacting survival following second surgery in patients with glioblastoma in the temozolomide treatment era, incorporating neutrophil/lymphocyte ratio and time to first progression.

Authors:  Mairéad G McNamara; Zarnie Lwin; Haiyan Jiang; Arnoud J Templeton; Gelareh Zadeh; Mark Bernstein; Caroline Chung; Barbara-Ann Millar; Normand Laperriere; Warren P Mason
Journal:  J Neurooncol       Date:  2014-01-28       Impact factor: 4.130

10.  Treatment of recurrent glioblastoma: can local delivery of mitoxantrone improve survival?

Authors:  Amerigo Boiardi; Antonio Silvani; Marica Eoli; Elena Lamperti; Andrea Salmaggi; Paola Gaviani; Anna Fiumani; Andrea Botturi; Chiara Falcone; Alessandra Solari; Graziella Filippini; Francesco Di Meco; Giovanni Broggi
Journal:  J Neurooncol       Date:  2008-02-19       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.